Synonym
NZ-419; HD-003; NZ 419; HD 003; NZ419; HD003
IUPAC/Chemical Name
1-methylimidazolidine-2,4-dione
InChi Key
RHYBFKMFHLPQPH-UHFFFAOYSA-N
InChi Code
InChI=1S/C4H6N2O2/c1-6-2-3(7)5-4(6)8/h2H2,1H3,(H,5,7,8)
SMILES Code
O=C1NC(CN1C)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
114.10
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Ienaga K, Sohn M, Naiki M, Jaffa AA. Creatinine metabolite, HMH (5-hydroxy-1-methylhydantoin; NZ-419), modulates bradykinin-induced changes in vascular smooth muscle cells. J Recept Signal Transduct Res. 2014 Jun;34(3):195-200. doi: 10.3109/10799893.2013.876039. PubMed PMID: 24641698.
2: Ienaga K, Park CH, Yokozawa T. Protective effect of an intrinsic antioxidant, HMH (5-hydroxy-1-methylhydantoin; NZ-419), against cellular damage of kidney tubules. Exp Toxicol Pathol. 2013 Jul;65(5):559-66. doi: 10.1016/j.etp.2012.05.001. PubMed PMID: 22749566.
3: Ienaga K, Yokozawa T. Creatinine and HMH (5-hydroxy-1-methylhydantoin, NZ-419) as intrinsic hydroxyl radical scavengers. Drug Discov Ther. 2011 Aug;5(4):162-75. PubMed PMID: 22466296.
4: Hasegawa G, Nakano K, Ienaga K. Serum accumulation of a creatinine oxidative metabolite (NZ-419: 5-hydroxy-1- methylhydatoin) as an intrinsic antioxidant in diabetic patients with or without chronic kidney disease. Clin Nephrol. 2011 Oct;76(4):284-9. PubMed PMID: 21955863.
5: Ienaga K, Yokozawa T. Treatment with NZ-419 (5-Hydroxy-1-methylimidazoline-2,4-dione), a novel intrinsic antioxidant, against the progression of chronic kidney disease at stages 3 and 4 in rats. Biol Pharm Bull. 2010;33(5):809-15. PubMed PMID: 20460759.
6: Ienaga K, Mikami H, Yokozawa T. First indications demonstrating the preventive effects of NZ-419, a novel intrinsic antioxidant, on the initiation and/or progression of chronic renal failure in rats. Biol Pharm Bull. 2009 Jul;32(7):1204-8. PubMed PMID: 19571386.
7: Gao L, Yang S, Liu J, Liu L. [Preventive effects of 5-hydroxy-1-methylhydantoin on paraquat-induced nephrotoxicity in rat]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2015 Apr;27(4):246-9. doi: 10.3760/cma.j.issn.2095-4352.2015.04.004. Chinese. PubMed PMID: 25891451.
8: Ienaga K, Nakamura K, Naka F, Goto T. The metabolism of 1-methylhydantoin via 5-hydroxy-1-methylhydantoin in mammals. Biochim Biophys Acta. 1988 Dec 15;967(3):441-3. PubMed PMID: 3196760.
9: Nakamura K, Ienaga K. Creatol (5-hydroxycreatinine), a new toxin candidate in uremic patients. Experientia. 1990 May 15;46(5):470-2. PubMed PMID: 2347396.
